DAURISMO Trademark

Trademark Overview

On Tuesday, December 4, 2018, a trademark application was filed for DAURISMO with the United States Patent and Trademark Office. The USPTO has given the DAURISMO trademark a serial number of 88215704. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 24, 2022. This trademark is owned by Pfizer Inc.. The DAURISMO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use
daurismo

General Information

Serial Number88215704
Word MarkDAURISMO
Filing DateTuesday, December 4, 2018
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 24, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, April 23, 2019

Trademark Statements

Indication of Colors claimedColor is not claimed as a feature of the mark.
Description of MarkThe mark consists of the word "DAURISMO" with a stylized circle surrounding the letters "SMO".
Goods and ServicesPharmaceutical preparations for the treatment of autoimmune, cardiovascular, central nervous system, endocrine, gastrointestinal, genetic, immunological, infectious, inflammatory, menopausal, metabolic, musculoskeletal, neurodegenerative, neurological, neuromuscular, ophthalmological, psychiatric, respiratory, urogenital, urological and viral diseases and disorders; pharmaceutical preparations for the treatment of blood disorders, liver disorders, erectile dysfunction, sexual dysfunction, cancer, pain and diabetes; pharmaceutical preparations, namely, antifungal preparations, dermatological preparations and smoking cessation preparations; vaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, December 21, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePfizer Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew York, NY 10017
Party NamePfizer Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10017

Trademark Events

Event DateEvent Description
Monday, January 24, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 24, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, September 14, 2021ASSIGNED TO EXAMINER
Wednesday, June 9, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, June 7, 2021EXTENSION 4 GRANTED
Monday, June 7, 2021EXTENSION 4 FILED
Monday, June 7, 2021TEAS EXTENSION RECEIVED
Wednesday, January 6, 2021CORRECTED NOA E-MAILED
Tuesday, January 5, 2021DIVISIONAL PROCESSING COMPLETE
Monday, November 9, 2020DIVISIONAL REQUEST RECEIVED
Monday, November 9, 2020TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, November 10, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 9, 2020EXTENSION 3 GRANTED
Sunday, November 8, 2020EXTENSION 3 FILED
Sunday, November 8, 2020TEAS EXTENSION RECEIVED
Friday, June 5, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 3, 2020EXTENSION 2 GRANTED
Wednesday, June 3, 2020EXTENSION 2 FILED
Wednesday, June 3, 2020TEAS EXTENSION RECEIVED
Tuesday, December 17, 2019CHANGES/CORRECTIONS AFTER PUB APPROVAL ENTERED
Monday, December 16, 2019ASSIGNED TO LIE
Friday, December 13, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, December 11, 2019EXTENSION 1 GRANTED
Wednesday, December 11, 2019EXTENSION 1 FILED
Wednesday, December 11, 2019TEAS EXTENSION RECEIVED
Wednesday, December 11, 2019APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, December 11, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, November 13, 2019TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Tuesday, June 18, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 23, 2019OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 23, 2019PUBLISHED FOR OPPOSITION
Wednesday, April 3, 2019NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, March 13, 2019APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, March 5, 2019ASSIGNED TO EXAMINER
Saturday, December 22, 2018NOTICE OF DESIGN SEARCH CODE E-MAILED
Friday, December 21, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, December 7, 2018NEW APPLICATION ENTERED IN TRAM

Related Keywords

daurismo preparations disorders pharmaceutical dysfunction treatment liver erectile blood viral urological